Centrinone-B (LCR323; LCR-323; LCR 323) is a novel and reversible polo-like kinase 4 (PLK4) inhibitor with potential anticancer activity. It inhibits PLK4 with a Ki of 0.59 nM and shows >1500-fold selectivity for inhibiting PLK4 over Aurora A and Aurora B.

纯度：≥98%

CAS：1798871-31-4